You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. DEVELOPING A NOVEL NON-VIRAL NANOPIECES GENE DELIVERY SYSTEM FOR AD GENE THERAPY

    SBC: Nanode Therapeutics, Inc.            Topic: 4

    To develop a new, safe, and efficacious non-viral gene delivery system crossing the blood-brain barrier (BBB) for gene therapy of Alzheimer’s Disease (AD).

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Caring4Caregivers: A theory-driven mobile solution to promote self-care and well-being among caregivers of individuals with Alzheimer’s andrelated dementias

    SBC: Pro-Change Behavior Systems, Inc.            Topic: R

    7. Project Summary/Abstract Over 11 million Americans are currently providing unpaid care to a family member or friend with Alzheimer's disease or a related dementia (ADRD). While caregiving can be a positive experience that brings meaning and an increased sense of purpose, it can also take a toll. Nearly 60% of ADRD caregivers rate their emotional distress as high or very high, and over 30% suffe ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Promoting adult hippocampal neurogenesis using antisense oligonucleotides as an Alzheimer's disease therapy

    SBC: BOLDEN THERAPEUTICS, INC.            Topic: NIA

    PROJECT SUMMARY There is an enormous need for therapeutics to prevent and treat Alzheimer's disease (AD). Adult Hippocampal Neurogenesis (AHN) is critical for normal learning and memory, but it declines in patients with AD. Work in animal models has underscored the role of AHN in improving cognition in the face of AD pathology. Thus, restoring AHN has emerged as an attractive target for an AD ther ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Entrepreneurial development award for a novel Alzheimer's disease therapeutic

    SBC: BOLDEN THERAPEUTICS, INC.            Topic: Y

    The aging population in the US and globally has led to an urgent need for therapeutics to prevent and treat Alzheimer's disease (AD). Adult Hippocampal Neurogenesis (AHN) is critical for normal learning and memory and declines in patients with AD. Work in animal models has underscored the role of AHN in improving cognition in the face of AD pathology. Thus, restoring AHN has emerged as an attracti ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Joyuus: A Web-based Tool for Postpartum Care Self-care to Address the Complex Needs of Underserved Women

    SBC: JOYUUS, LLC            Topic: 100

    PROJECT SUMMARY/ABSTRACT In the United States, the postpartum period is a critical time for both maternal and child health; the US maternal mortality rate is the highest among other developed, high-income countries. More than half of all maternal deaths occur postpartum, from one day to one year after birth.1-9 There are vast racial and ethnic disparities in maternal mortality and severe morbidity ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a selective PI3K-Akt-activating neurotrophic small molecule drug, MT-002, for the healing of corneal wounds in Neurotrophic Keratitis.

    SBC: CALISTA THERAPEUTICS INC            Topic: NEI

    Calista is developing topical MT-002, a selective PI3K-Akt activator that safely restores normal wound healing in a clinically predictive animal model of Neurotrophic Keratitis (NK). NK causes progressive corneal damage that can lead to corneal perforation, ulceration and blindness. NK is caused by a loss of nerve sensation from the brain to the eye, decreasing growth factor release that stimulate ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. FHIR-ed Up for Tobacco Cessation

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NHLBI

    Summary Tobacco use remains the leading preventable cause of death in the US, contributing to more than 480,000 premature deaths each year. The well-established Tobacco Treatment Guidelines and recently released American College of Cardiology Expert Consensus Decision Pathway for tobacco cessation treatment underscore the need to conceptualize tobacco use as a chronic substance use disorder and to ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Epilepsy Seizure Detection with Innovative Tripolar EEG (tEEG)

    SBC: CREMEDICAL CORP            Topic: NINDS

    PROJECT SUMMARY Electroencephalography (EEG) is an essential component in the evaluation of epilepsy, the most common serious brain disorder worldwide. Misdiagnosis of epilepsy is very common and occurs in up to 50% of the patients. Artifact contamination seriously hinders the effectiveness of EEG and is a root cause of misdiagnosis. CREmedical is developing a tripolar concentric ring electrode (T ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Radiological Emergency Responder Field Team Route Training Simulation Using Gaming Technology and Commonly Used Atmospheric Model Outputs

    SBC: Radiation Emergency Services, LLC            Topic: NIEHS

    Project Summary Attachment In the radiological response community, with the exception of a limited number of large-scale exercises, there is a gap in technology that hinders hands-on survey training. Even when there is an available exercise, the compressed time sequence prevents realistic practice for some players, particularly field survey teams. The goal of this Phase I project is to initiate ef ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. A novel agent to manage thrombocytopenic patients with platelet transfusion refractoriness

    SBC: FIBROPLATE INC            Topic: NHLBI

    PROJECT SUMMARY Platelet Transfusion Refractoriness (PTR) or the failure to achieve the desired level of blood platelets after platelet transfusion, hampers the management of bleeding episodes in thrombocytopenic patients. PTR condition is associated with a high risk of severe bleeding complications and reduced survival rate, longer hospital stays and higher hospital costs. Existing management str ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government